Laurus Labs Board Recommends S.R. Batliboi & Associates as New Statutory Auditors

2 min read     Updated on 12 Mar 2026, 06:53 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Laurus Labs Limited's Board of Directors recommended the appointment of S.R. Batliboi & Associates LLP as statutory auditors for a five-year term from 2027-2032, subject to shareholder approval. The recommendation was made on March 12, 2026, following the Audit Committee's recommendation. The new auditors will replace Deloitte Haskins & Sells LLP after they complete their second term at the 22nd AGM in 2027.

34867414

*this image is generated using AI for illustrative purposes only.

Laurus Labs Limited's Board of Directors has recommended a change in the company's statutory auditors, marking a significant corporate governance development. The recommendation was made during a board meeting held on March 12, 2026, following the Audit Committee's recommendation.

Board Recommendation Details

The board has recommended the appointment of S.R. Batliboi & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 101049W/E300004) as the new statutory auditors. This appointment is subject to approval by the company's shareholders at the upcoming Annual General Meeting.

Parameter: Details
Recommended Auditor: S.R. Batliboi & Associates LLP
ICAI Registration: 101049W/E300004
Term Duration: 5 consecutive years
Start Date: Conclusion of 22nd AGM (2027)
End Date: Conclusion of 27th AGM (2032)
Board Meeting Date: March 12, 2026

Transition from Current Auditors

Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018) will continue as the company's statutory auditors until the conclusion of the 22nd Annual General Meeting to be held in 2027. By that time, Deloitte will have completed their second term as statutory auditors for the company.

The transition represents a planned change following the completion of the current auditors' tenure, ensuring continuity in the company's audit processes while bringing fresh perspective through the new appointment.

About S.R. Batliboi & Associates LLP

S.R. Batliboi & Associates LLP was incorporated in India in 1949 with its registered office in Kolkata and maintains offices across key cities in India. The firm operates as part of the S.R. Batliboi & Affiliates network, which includes several entities primarily engaged in providing audit and assurance services.

The network firms audit numerous large listed and private companies across diverse market segments, including:

  • Pharmaceutical companies
  • Industrial and Infrastructure sectors
  • Consumer Products
  • Financial Services
  • Technology, Media and Entertainment
  • Telecommunications
  • Professional Services

Meeting and Approval Process

The board meeting commenced at 06.00 p.m. (IST) and concluded at 06.35 p.m. (IST) on March 12, 2026. The resolution relating to the appointment of S.R. Batliboi & Associates LLP will be proposed to shareholders for approval at the 22nd Annual General Meeting of the company to be held in 2027.

This appointment follows regulatory requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the company has provided all necessary disclosures as required under the applicable regulations and SEBI Master Circular guidelines.

Historical Stock Returns for Laurus Labs

1 Day5 Days1 Month6 Months1 Year5 Years
+0.56%+1.57%+3.27%+16.88%+82.32%+188.26%

Laurus Labs Records Rs. 59.98 Crore Block Trade on NSE

0 min read     Updated on 02 Mar 2026, 09:30 AM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Laurus Labs recorded a significant block trade worth Rs. 59.98 crores on NSE involving 563,347 shares at Rs. 1064.70 per share. The transaction represents substantial institutional activity in the pharmaceutical company's stock, typically indicating large-scale buying or selling by institutional investors.

33969633

*this image is generated using AI for illustrative purposes only.

Laurus labs witnessed significant institutional trading activity with a substantial block trade executed on the National Stock Exchange (NSE). The transaction represents one of the notable trading activities in the pharmaceutical sector.

Block Trade Details

The block trade involved substantial market activity with the following parameters:

Parameter: Details
Total Value: Rs. 59.98 crores
Number of Shares: 563,347 shares
Price per Share: Rs. 1064.70
Exchange: NSE

Market Significance

Block trades typically represent large institutional transactions that are executed outside the regular market to avoid significant price impact. Such transactions often involve mutual funds, insurance companies, foreign institutional investors, or other large market participants looking to buy or sell substantial quantities of shares.

The execution price of Rs. 1064.70 per share for this transaction indicates the level at which institutional investors were willing to transact in Laurus Labs stock. The substantial volume of 563,347 shares demonstrates significant institutional interest in the pharmaceutical company's equity.

Historical Stock Returns for Laurus Labs

1 Day5 Days1 Month6 Months1 Year5 Years
+0.56%+1.57%+3.27%+16.88%+82.32%+188.26%

More News on Laurus Labs

1 Year Returns:+82.32%